InvestorsHub Logo
Followers 234
Posts 26887
Boards Moderated 0
Alias Born 01/12/2013

Re: None

Friday, 05/31/2013 9:20:13 AM

Friday, May 31, 2013 9:20:13 AM

Post# of 426185
AstraZeneca and Abbott end license agreement for the development of Certriad
AZN combo history:
http://www.astrazeneca.com/Media/Press-releases/Article/AstraZeneca-ends-agreement-with-Abbott-for-Certriad

Wednesday, 22 December 2010

AstraZeneca announced today that it has notified Abbott that it will discontinue the development of CERTRIAD (rosuvastatin calcium and fenofibric acid), which was being investigated for the treatment of mixed dyslipidemia. This means the co-development and license agreement with Abbott will end on 22 January 2011.

A Complete Response Letter (CRL) for the CERTRIAD New Drug Application (NDA) was received from the U.S. Food and Drug Administration (FDA) on 30 March 2010.

The companies reached this decision after careful review and consideration of the CRL and the resulting regulatory delay, and have determined that the development of CERTRIAD is no longer commercially attractive.

AstraZeneca will continue to focus on other development priorities both within and outside of the cardiovascular disease therapeutic area.


"Certriad" results
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262365/table/t4-cpaa-2-095/

IMO didn't pass the FDA safety risk test. Amarin, had superior lab results and no safty issues. AZN is just dick'n with Amarin now.

Amarin & Elan Achor launch sounds good to me.

Williams
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News